CLAIMS

1. Use of a pharmaceutical composition ~~of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof~~ in the ~~manufacture of a medicament~~preparation of drugs for the treatment~~ing~~ of a female patient suffering from non-small cell lung cancer, wherein

the pharmaceutical composition comprises 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof; and

an effective amount of ranges of of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof ranges from 0.01-10 grams per dose; and

the patient is a non-smoker or never smoker.

~~2. The use of claim 1, wherein the patient is a non-smoker.~~

~~3~~2. The use of claim ~~2~~1, wherein the non-small cell lung cancer is lung adenocarcinoma.

~~4~~3. The use of claim 1, wherein the ~~medicament~~ drugs ~~is~~are to be administered to the patient in need thereof, and a second therapeutic agent useful in the treatment of non-small cell lung cancer is to be co-administered to the patient.

~~5~~4. The use of claim ~~4~~3, wherein the second therapeutic agent is paclitaxel or cisplatin.

~~6~~5. The use of claim ~~4~~3, wherein the second therapeutic agent is selected from camptothecin derivatives, paclitaxel, docetaxel, epothilone B, 5-FU, gemcitabine, oxaliplatin, cisplatinum, carboplatin, melphalam, dacarbazine, temozolomide, doxorubicin, imatinib, erlotinib, bevacizumab, and cetuximab.

~~7~~6. The use of claim ~~4~~3, wherein the non-small cell lung cancer is EGFR mutant positive non-small cell lung cancer.

~~8. The use of Claim 1, wherein the medicament comprising 10-40 grams per dose of the 2,2'-dithio-bis-ethane sulfonate, or the pharmaceutically-acceptable salt is to be administered to the patient.~~

~~9. The use of claim 1, wherein the patient is a never smoker.~~

~~10~~7. Use of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof and a second therapeutic agent in the manufacture of a pharmaceutical composition for the treatment~~ing~~ of advanced and/or metastatic non-small cell lung cancer in female patients, wherein the pharmaceutical composition is to be administered to a human patient having non-small cell lung cancer who has received a second-line or a higher-line therapy, wherein

an effective amount of ranges of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof ranges from 0.01-10 grams per dose; and

each of the female patient is a non-smoker or never smoker.

~~11~~8. The use of claim ~~10~~7, wherein non-small cell lung cancer is EGFR mutation negative non-small cell lung cancer.

~~12~~9. The use of claim ~~10~~7, wherein the second therapeutic agent is paclitaxel or cisplatin.

~~13~~10. Use of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof in the manufacture of a composition for the treat~~ing~~ment ~~ing~~ of a female, nonsmoking patient suffering from non-small cell lung cancer, wherein

the patient is to be determined as a non-smoker; and

the composition comprises an effective amount of ranges of 2,2'-dithio-bis-ethane sulfonate, or a pharmaceutically-acceptable salt thereof ranging from 0.01-10 grams per dose.

~~14~~11. The of use of Claim ~~13~~10, wherein testing for EGFR mutants is to be carried out.

~~15~~12. The use of claim ~~13~~11, wherein the composition is to be administered to the non-smoker, and a second therapeutic agent useful in the treatment of non-small cell lung cancer is to be co-administered to the non-smoker.

~~16~~13. The use of claim ~~15~~12, wherein the second therapeutic is paclitaxel or cisplatin.

~~17~~14. The use of claim ~~15~~12, wherein the second therapeutic agent is selected from camptothecin derivatives, paclitaxel, docetaxel, epothilone B, 5-FU, gemcitabine, oxaliplatin, cisplatinum, carboplatin, melphalam, dacarbazine, temozolomide, doxorubicin, imatinib, erlotinib, bevacizumab, and cetuximab.

~~18. The use of claim 16, wherein the composition comprises an effective amount of ranges of 2,2'-dithio-bis-ethane sulfonate, or the pharmaceutically-acceptable salt thereof ranging from 0.01-10 grams per dose.~~

~~19~~15. The use of claim ~~13~~10, wherein the non-small cell lung cancer is to be further determined as ALK, ROS, MET, EGFR mutant-positive non-small cell lung cancer.

~~20~~16. The use of claim ~~13~~10, wherein the non-small cell lung cancer is to be determined to include ALK and ROS1 gene fusions/rearrangements, EGFR gene mutations/deletions, and MET/HGFR gene amplifications.